Share on LinkedInShare on LinkedIn

ARTICLE · 11 OCTOBER 2023

Relief For US Applicants - EPO Takes A Pragmatic Decision On Priority

The EPO's Enlarged Board of Appeal has issued a decision favouring patent applicants on the often tricky question of priority. This may come as a relief to US-based applicants...

United StatesIntellectual Property

The EPO's Enlarged Board of Appeal has issued a decision favouring patent applicants on the often tricky question of priority. This may come as a relief to US-based applicants, particularly with pre-AIA priority applications.

BACKGROUND

We previously reported that the EPO's Boards of Appeal had requested clarification of matters relating to priority. The issue has implications for many applications, particularly PCT applications with pre-AIA priority applications.

The issue arose during an opposition against Alexion Pharmaceuticals' patent EP1755674, and the Board of Appeal referred the following questions of law to the Enlarged Board of Appeal:

  1. Does the EPC confer jurisdiction on the EPO to determine whether a party validly claims to be a successor in title as referred to in Article 87(1)(b) EPC?

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from